Willingness to participate in research among black patients with liver disease: A national cross‐sectional study-Reference-Cited by-同舟云学术

Willingness to participate in research among black patients with liver disease: A national cross‐sectional study

Published:2021-04-26 Issue:7 Volume:28 Page:982-993
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

McGuire F. Hunter¹²^ORCID,André Kat²³,Bradsher Minyone L.²,Harrison Dawn⁴,Sterling Richard K.⁵,Reddy K. Rajender⁶^ORCID,Serper Marina⁶,Golin Carol E.¹⁷,Reau Nancy⁸,Lim Joseph K.⁹^ORCID,Nelson David R.¹⁰,Sarkar Souvik¹¹,Evon Donna M.²⁴

Affiliation:

1. Department of Health Behavior UNC Gillings School of Global Public Health Chapel Hill NC USA

2. Center for Gastrointestinal Biology and Disease UNC School of Medicine Chapel Hill NC USA

3. College of Psychology Nova Southeastern University Fort Lauderdale FL USA

4. Division of Gastroenterology and Hepatology UNC School of Medicine Chapel Hill NC USA

5. Division of Gastroenterology Hepatology & Nutrition Virginia Commonwealth University Richmond VA USA

6. Division of Gastroenterology and Hepatology University of Pennsylvania Perelman School of Medicine Philadelphia PA USA

7. Division of General Medicine and Epidemiology UNC School of Medicine Chapel Hill NC USA

8. Department of Internal Medicine Section of Hepatology Rush University Medical Center Chicago IL USA

9. Digestive Diseases Department of Internal Medicine Yale School of Medicine New Haven CT USA

10. Division of Gastroenterology, Hepatology, and Nutrition Department of Medicine University of Florida Jacksonville FL USA

11. Division of Gastroenterology and Hepatology University of California Davis School of Medicine Sacramento CA USA

Funder

Merck

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13493

Reference47 articles.

1. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002

2. Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

3. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

4. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent

5. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Implementing pragmatic clinical trials in hepatology;Hepatology;2023-02-27

2. Underrepresentation of Racial and Ethnic Minorities in High-Impact Cirrhosis Clinical Trials;Clinical Gastroenterology and Hepatology;2022-11